Plain-English translation of NCT07278661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called romiplostim—an injection that helps increase blood platelets—to see if it can safely prepare patients with low platelet counts for heart surgery. Romiplostim has worked well in other conditions, and researchers believe it may help patients who currently cannot have needed cardiac surgery because their platelet levels are too low. The study will compare the medication to a placebo (inactive injection) to see if it truly makes a difference.
Some patients need life-saving heart surgery but cannot have it safely because their blood platelet counts are dangerously low. This medication has been successful in other medical situations, so researchers want to test whether it can help these patients prepare for surgery without complications.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the study medication or a placebo as an injection under your skin 10 to 14 days before your scheduled heart surgery. You will be admitted to the hospital before surgery and closely watched for at least 10 days afterward with blood tests and clinical checkups so doctors can catch any side effects quickly. The entire study period will span from your first injection through your recovery after surgery.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
France